Imipramine on ER+ve and Triple Negative Breast Cancer

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 5, 2019

Primary Completion Date

March 1, 2022

Study Completion Date

May 1, 2022

Conditions

Breast Cancer

Interventions

DRUG

Imipramine

Imipramine will be given daily for 21-30 days.

Trial Locations (1)

Mays Cancer Center, UT Health San Antonio, San Antonio

All Listed Sponsors

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT03122444 - Imipramine on ER+ve and Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter